Skip to main content

Pharma Equity Group A/S (CPH:PEG)

Denmark flag Denmark · Delayed Price · Currency is DKK
0.0888
-0.0002 (-0.22%)
Apr 28, 2026, 3:19 PM CET
10.45%
Market Cap 109.25M
Revenue (ttm) n/a
Net Income (ttm) -25.38M
Shares Out 1.23B
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,592
Average Volume 446,268
Open 0.0912
Previous Close 0.0890
Day's Range 0.0832 - 0.0912
52-Week Range 0.0730 - 0.1500
Beta 1.05
RSI 52.35
Earnings Date Aug 14, 2026

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of color... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 5
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol PEG
Full Company Profile

Financial Performance

Financial Statements

News

Pharma Equity Group Transcript: Investor Update

A capital reduction and subsequent increase enabled a DKK 51 million raise, reducing debt by DKK 38.5 million and diluting shareholders by 17%. Focus is on securing further funding, advancing clinical studies, and finalizing a licensing deal by late 2025.

1 year ago - Transcripts

Pharma Equity Group Earnings Call Transcript: Q2 2024

Positive clinical progress and strategic focus on licensing and capital structure mark the half-year, with increased costs due to organizational growth and a maintained loss guidance of DKK 24–29 million. A capital increase is planned with minimal expected dilution.

1 year ago - Transcripts

Pharma Equity Group Transcript: Investor Update

A new commercial relationship director is leading efforts to expand clinical and industry networks, conduct in-depth market analysis, and identify strategic partners with financial and development strength. The goal is to secure the first partnership in 2025, with flexible agreement structures and a global focus.

2 years ago - Transcripts

Pharma Equity Group Earnings Call Transcript: Q3 2023

2 years ago - Transcripts